The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells

• Published in: Biomedicine & pharmacotherapy 2018-10, Vol.106, p.1742-1750
• Main Authors: Ghasemimehr, Narges, Farsinejad, Alireza, Mirzaee Khalilabadi, Rooholla, Yazdani, Zinat, Fatemi, Ahmad
• Format: Article
• Language: English
• Subjects: Apoptosis - drug effects; Benzamides - pharmacology; Benzamides - therapeutic use; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Doxorubicin - pharmacology; Doxorubicin - therapeutic use; Drug Synergism; Drug Therapy, Combination; Humans; MST-312; pre-B ALL; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology; Telomerase; Topoisomerase II Inhibitors - pharmacology; Topoisomerase II Inhibitors - therapeutic use
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2018.07.140

[Display omitted] •MST-312/doxorubicin synergistically decreases cell viability of pre-B ALL cells.•MST-312 potentiates the cytotoxicity of pre-B ALL cells in response to doxorubicin.•MST-312 amplifies doxorubicin-induced apoptosis in NALM-6 and REH cells.•MST-312/doxorubicin-induced apoptosis proceeds through increased Bax/Bcl-2 ratio.•MST-312/doxorubicin down-regulates the expression of c-Myc and hTERT genes. There have been consistent efforts in concomitant administration of chemotherapeutic agents such as doxorubicin beside other more tumor-specific drugs in order to increase sensitivity of tumor cells to the cytotoxicity of doxorubicin and reduce necessary chemotherapeutic dosage. Telomerase-targeted therapy for cancer has received great attention because telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. The present study was aimed to investigate the effect of telomerase inhibitor MST-312, a chemically modified derivative of epigallocatechin gallate (EGCG), on doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells. The pre-B ALL cell lines (NALM-6 and REH) were cultured and treated with MST-312 and doxorubicin, separately and in combination. Cell viability was measured by trypan blue staining and MTT assay. Annexin-V/7-AAD staining by flow cytometry was used for evaluation of apoptosis. Gene expression of hTERT, c-Myc, Bax and Bcl-2, was detected by the quantitative Real-Time PCR. Our results showed that MST-312 exerted dose-dependent short-term cytotoxic and apoptotic effects on pre-B ALL cells. Combination of MST-312 and doxorubicin synergistically enhanced the cytotoxicity and apoptosis of both NALM-6 and REH cells. Consistently, apoptosis induction by the combined treatment was associated with significant reduction of Bcl-2, c-Myc and hTERT, and a marked increase of Bax mRNA expression levels, compared with the single treatments. Our data suggest that the synergistic anticancer effect induced by combination of MST-312 and doxorubicin represents a novel treatment strategy for pre-B ALL.